Hair loss drug probed in Europe over link to suicidal thoughtsThe European Medicines Agency is reviewing finasteride for links to suicidal thoughts and behaviors, amid concerns over psychiatric side effects.
EU regulator rejects Alzheimer's drug lecanemabThe European Medicines Agency (EMA) rejected a license for an Alzheimer's treatment due to serious side effects outweighing benefits.
Europe sidelines Alzheimer's drug: lessons must be learntThe EMA's cautious approach may deny patients access to effective Alzheimer's treatment, contrasting with global acceptances of lecanemab.
A scientific rebellion to get Europe to approve a controversial Alzheimer's drugLecanemab represents a breakthrough for Alzheimer's treatment but faces significant controversy regarding its efficacy, safety, and accessibility.
EU regulator rejects Alzheimer's drug lecanemabThe European Medicines Agency (EMA) rejected a license for an Alzheimer's treatment due to serious side effects outweighing benefits.
Europe sidelines Alzheimer's drug: lessons must be learntThe EMA's cautious approach may deny patients access to effective Alzheimer's treatment, contrasting with global acceptances of lecanemab.
A scientific rebellion to get Europe to approve a controversial Alzheimer's drugLecanemab represents a breakthrough for Alzheimer's treatment but faces significant controversy regarding its efficacy, safety, and accessibility.